In Brief: Ranitidine Returns

The FDA has approved a new tablet formulation of the H2-receptor antagonist (H2RA) ranitidine from one manufacturer (VKT Pharma/Rising Pharma). It is only available by prescription. In 2020, the FDA requested that all formulations of ranitidine be withdrawn from the market because unacceptable levels of the nitrosamine compound N-nitrosodimethylamine (NDMA), a potentially carcinogenic contaminant, had been detected in ranitidine samples.